Compare Cytokinetics Inc (CYTK) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Simon Property Group Inc — how do they compare? Cytokinetics Inc trades at $73.45 (market cap $10.52B), while Simon Property Group Inc trades at $221.47 (market cap $71.36B). The key difference: Simon Property Group Inc is far larger — about 6.8× Cytokinetics Inc's market cap, and Simon Property Group Inc pays a 4.04% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | SPG | |
|---|---|---|
Market Cap | $10.52B | $71.36B |
Sector | Technology | Real Estate |
52-Week High | $87.26 | $236.70 |
52-Week Low | $35.33 | $172.19 |
Enterprise Value | $10.62B | $99.81B |
Dividend Yield | — | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 1.06% with a bearish technical signal. The company shows strong commercial momentum with Myqorzo gaining traction internationally, but faces significant financial challenges including negative gross margin of -372.55% and net income margin of -1,321.12%. Recent Q2 2026 earnings beat revenue estimates despite posting losses, while regulatory approvals in the UK expand market access.
Investment outlook balances promising drug pipeline against substantial financial losses. Analyst consensus remains overwhelmingly bullish with 97% buy ratings and $111.14 price target, representing 47% upside potential. Key risks include high cash burn, competitive pressures, and the need for continued financing to support operations and drug development.
Simon Property Group (SPG) trades at $221.47, up 0.88% with a bearish technical signal despite strong fundamentals. The REIT reported Q2 2026 EPS of $1.49, missing estimates, but raised full-year FFO guidance on robust leasing and 96% occupancy. Valuation metrics show a P/E of 15.57 and ROE of 135.7%, supported by $4.63B net income in 2025. Recent news highlights operational strength amid cautious analyst sentiment.
Outlook balances high profitability and dividend yield against technical weakness and debt levels. Upside exists if leasing momentum sustains, but risks include interest rate sensitivity and retail sector headwinds. Analysts see modest upside to $228.55 target, with 40.5% buy ratings reflecting tempered optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
